April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Endophtalmitis Following Intravitreal Injection of Anti VEGF Therapy : A Multicentric Study
Author Affiliations & Notes
  • A. A. Alezzandrini
    Oftalmos, Buenos Aires, Argentina
  • M. Charles
    Instituto Oftalmologico Dr Charles, Buenos Aires, Argentina
  • M. J. Saravia
    Ophthalmology /Retina, Hospital Austral, Buenos Aires, Argentina
  • G. Iribarren
    University of Buenos Aires, Buenos Aires, Argentina
  • M. Zas
    Ophthalmology, University of Buenos Aires, Capital Federal, Argentina
  • A. Bastien
    Universidad de Buenos Aires, Buenos Aires, Argentina
  • D. Bar
    Hospital Alemán, Buenos Aires, Argentina
  • E. Rosendi
    Hospital Pedro Lagleyze, Buenos Aires, Argentina
  • M. Garcia
    Oftalmos, Buenos Aires, Argentina
  • M. Della Savia
    Oftalmos, Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships  A.A. Alezzandrini, None; M. Charles, None; M.J. Saravia, None; G. Iribarren, None; M. Zas, None; A. Bastien, None; D. Bar, None; E. Rosendi, None; M. Garcia, None; M. Della Savia, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2807. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. A. Alezzandrini, M. Charles, M. J. Saravia, G. Iribarren, M. Zas, A. Bastien, D. Bar, E. Rosendi, M. Garcia, M. Della Savia; Endophtalmitis Following Intravitreal Injection of Anti VEGF Therapy : A Multicentric Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2807.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To identify the incidence of endophthalmitis after intravitreal anti VEGF injections (Bevacizumab) and report the clinical outcomes in our practice.

Methods: : Retrospective multicentric analysis of 6040 intravitreal anti VEGF injections (Bevacizumab - Avastin) applied from July 2005 through July 2009 in several Argentinian Ophthalmologic Centres. 5418 (89,7%) of the applications were performed in operating rooms under strict antiseptic conditions and 622 (10,3%) of the injections were made in a physician's office, also following the same strict measures.

Results: : Endophthalmitis developed in 2 of the 6040 eyes (0.03%) after anti VEGF pars plana injections.In every case, signs and symptoms of endophthalmitis appeared within 2 days from the injection, and both patients had received the anti VEGF injection in operating rooms. The microorganisms recovered were staphylococcus aureus and coagulase-negative staphylococcus.

Conclusions: : AntiVEGF applied via pars plana, whether made in operating rooms or in physicians office is a safe procedure for treating several retinal diseases.

Keywords: clinical (human) or epidemiologic studies: prevalence/incidence • endophthalmitis • injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.